Azithro is indicated for infections caused by susceptible organisms: in lower respiratory tract infections including bronchitis and pneumonia, in odontostomatological infections in skin and soft tissue infections. In acute otitis media and in upper respiratory tract infections including sinusitis and pharyngitis/tonsillitis. (Penicillin is the usual drug of choice in the treatment of Streptococcus pyogenes pharyngitis, including the prophylaxis of rheumatic fever.)
In sexually transmitted diseases in men and women, Azithro is indicated in the treatment of uncomplicated genital infections due to Chlamydia trachomatis. It is also indicated in the treatment of chancroid due to Haemophilus ducreyi, and uncomplicated genital infection due to non-multiresistant Neisseria gonorrhoeae, concurrent infection with Treponema pallidum should be excluded.
Azithro is indicated, either alone or in combination with rifabutin, for prophylaxis against Mycobacterium avium-intracellular complex (MAC) infection, an opportunistic infection prevalent in patients with advance human immunodeficiency virus (HIV).
Azithro is indicated in combination with ethambutol for the treatment of disseminated MAC (DMAC) infection in patients with advanced HIV infection.